Today: 29 April 2026
IonQ stock tumbles again as short-seller report hangs over quantum trade
5 February 2026
2 mins read

IonQ stock tumbles again as short-seller report hangs over quantum trade

New York, February 5, 2026, 13:51 EST — Regular session

  • IonQ shares dropped roughly 11% in afternoon trading, deepening the steep decline in the quantum-computing sector.
  • Wolfpack Research released a short report challenging IonQ’s dependence on U.S. defense funding. IonQ has denied the claims.
  • Investors are turning to IonQ’s February 25 results and any additional comments from the company for clearer insight.

Shares of IonQ, Inc. fell roughly 11% to $31.49 in Thursday afternoon trading, after hitting a high of $34.79 earlier and dropping to a low of $31.36. The stock closed $3.86 lower than Wednesday’s finish.

The slide adds strain to a heavily traded quantum-computing stock as investors grapple with fresh doubts over the stability of the company’s revenue stream — and whether the upcoming earnings report will offer any clarity, even for a moment.

IonQ now serves as a barometer for how eager investors are about quantum computing—a sector that offers revolutionary problem-solving tools but remains in its infancy commercially. When skepticism hits, the stock tends to swing sharply both ways.

Wolfpack Research revealed a short position on IonQ, releasing a report focused on the company’s Pentagon-linked funding.

Wolfpack’s report claimed IonQ lost funding from U.S. defense contracts, which made up a significant chunk of its revenue in recent years. It also questioned how the company reported “bookings,” a metric for expected future business not yet recorded as revenue. IonQ fired back, labeling the report as “false, misleading, and unsubstantiated.” Wolfpack founder and CEO Dan David countered, saying, “We’re providing transparency, and government earmarks do not.” Fortune

IonQ said Wednesday it plans to release its fourth-quarter and full-year 2025 financial results on Feb. 25, after the market closes. The company will follow up with a conference call at 4:30 p.m. Eastern to review the numbers and provide an outlook.

The timing is crucial since short-seller allegations usually stick around until a company releases its earnings, guidance, and—just as vital—more detailed disclosure on revenue breakdowns and customer pipelines. In IonQ’s case, government-related contracts have repeatedly drawn investor attention.

The slump wasn’t limited to just one player. Shares of other U.S.-listed quantum firms also tumbled, with Rigetti Computing and D-Wave Quantum each dropping around 11%, while Quantum Computing Inc slipped close to 10%.

Thursday’s action was notable despite a milder drop in the wider market. The Invesco QQQ Trust slipped roughly 1%, while the Technology Select Sector SPDR Fund fell around 1.3%.

Investors will be looking to see if IonQ provides more clarity on the contested issues, such as its classification of government-related projects. They’ll also watch for any deeper financial breakdowns that could allow the market to scrutinize the short thesis more closely.

That said, a feedback loop could emerge: disputed allegations might still dampen sentiment, tighten funding for volatile sectors, and trigger increased trading in downside hedges. Shares could stay under pressure if earnings guidance remains cautious or fails to provide fresh insights.

On Feb. 25, IonQ will release its Q4 and full-year results after the market closes. The company’s conference call is set for 4:30 p.m., marking the next opportunity for management to respond directly to the claims.

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Cambridge, Massachusetts, April 29, 2026, 09:04 EDT Biogen Inc. cut its full-year profit outlook on Wednesday, taking some shine off a first-quarter earnings beat driven by stronger sales of its Alzheimer’s drug Leqembi and newer rare-disease medicines. The Cambridge, Massachusetts-based drugmaker now expects 2026 adjusted earnings of $14.25 to $15.25 a share, down $1 at both ends of its prior range. Biogen said the cut reflects acquired in-process research and development charges, meaning costs tied to buying or licensing drug programs that are still being developed and have not yet become commercial products. The revision matters because Biogen is trying
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Caterpillar stock slips as insider sales surface and U.S. job data keeps traders edgy
Previous Story

Caterpillar stock slips as insider sales surface and U.S. job data keeps traders edgy

Coupang stock sinks nearly 10% as fresh data leak, U.S. subpoena rattle CPNG shares
Next Story

Coupang stock sinks nearly 10% as fresh data leak, U.S. subpoena rattle CPNG shares

Go toTop